nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—TLN1—osteoporosis	0.00105	0.00566	CbGpPWpGaD
Dabigatran etexilate—CES1—NRF2 pathway—AGER—osteoporosis	0.00103	0.00559	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—VCL—osteoporosis	0.00103	0.00558	CbGpPWpGaD
Dabigatran etexilate—Hypertension—Pamidronate—osteoporosis	0.00101	0.00124	CcSEcCtD
Dabigatran etexilate—Urticaria—Estropipate—osteoporosis	0.00101	0.00124	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Raloxifene—osteoporosis	0.00101	0.00123	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Etidronic acid—osteoporosis	0.001	0.00123	CcSEcCtD
Dabigatran etexilate—Haematuria—Estradiol—osteoporosis	0.001	0.00123	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Estropipate—osteoporosis	0.001	0.00123	CcSEcCtD
Dabigatran etexilate—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000999	0.00123	CcSEcCtD
Dabigatran etexilate—Infection—Risedronate—osteoporosis	0.000996	0.00122	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Estradiol—osteoporosis	0.000995	0.00122	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Ibandronate—osteoporosis	0.000995	0.00122	CcSEcCtD
Dabigatran etexilate—Arthralgia—Pamidronate—osteoporosis	0.000994	0.00122	CcSEcCtD
Dabigatran etexilate—Back pain—Conjugated Estrogens—osteoporosis	0.000994	0.00122	CcSEcCtD
Dabigatran etexilate—Urticaria—Alendronate—osteoporosis	0.000993	0.00122	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—SOD2—osteoporosis	0.000993	0.00538	CbGpPWpGaD
Dabigatran etexilate—Epistaxis—Estradiol—osteoporosis	0.000992	0.00122	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Alendronate—osteoporosis	0.000988	0.00121	CcSEcCtD
Dabigatran etexilate—Sinusitis—Estradiol—osteoporosis	0.000987	0.00121	CcSEcCtD
Dabigatran etexilate—Shock—Risedronate—osteoporosis	0.000987	0.00121	CcSEcCtD
Dabigatran etexilate—Anaemia—Zoledronate—osteoporosis	0.000986	0.00121	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Risedronate—osteoporosis	0.000983	0.00121	CcSEcCtD
Dabigatran etexilate—UGT1A9—Biological oxidations—CYP27A1—osteoporosis	0.000982	0.00532	CbGpPWpGaD
Dabigatran etexilate—Angioedema—Zoledronate—osteoporosis	0.000975	0.0012	CcSEcCtD
Dabigatran etexilate—Skin disorder—Risedronate—osteoporosis	0.000974	0.00119	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Calcitriol—osteoporosis	0.000974	0.00119	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Raloxifene—osteoporosis	0.000972	0.00119	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—CYP27A1—osteoporosis	0.000968	0.00524	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Ibandronate—osteoporosis	0.000967	0.00119	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—PTH1R—osteoporosis	0.000962	0.00521	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CALCR—osteoporosis	0.000962	0.00521	CbGpPWpGaD
Dabigatran etexilate—Abdominal pain—Ibandronate—osteoporosis	0.000962	0.00118	CcSEcCtD
Dabigatran etexilate—Syncope—Zoledronate—osteoporosis	0.000957	0.00117	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Pamidronate—osteoporosis	0.000953	0.00117	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Estradiol—osteoporosis	0.000949	0.00116	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—GPX1—osteoporosis	0.000947	0.00513	CbGpPWpGaD
Dabigatran etexilate—Infection—Pamidronate—osteoporosis	0.000947	0.00116	CcSEcCtD
Dabigatran etexilate—Urticaria—Calcitriol—osteoporosis	0.000946	0.00116	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Estradiol—osteoporosis	0.000945	0.00116	CcSEcCtD
Dabigatran etexilate—Palpitations—Zoledronate—osteoporosis	0.000943	0.00116	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Calcitriol—osteoporosis	0.000942	0.00115	CcSEcCtD
Dabigatran etexilate—Angioedema—Conjugated Estrogens—osteoporosis	0.000939	0.00115	CcSEcCtD
Dabigatran etexilate—Shock—Pamidronate—osteoporosis	0.000938	0.00115	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Zoledronate—osteoporosis	0.000938	0.00115	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Estropipate—osteoporosis	0.000935	0.00115	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Pamidronate—osteoporosis	0.000935	0.00115	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Pamidronate—osteoporosis	0.000933	0.00114	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Estradiol—osteoporosis	0.000933	0.00114	CcSEcCtD
Dabigatran etexilate—Vomiting—Etidronic acid—osteoporosis	0.000933	0.00114	CcSEcCtD
Dabigatran etexilate—Cough—Zoledronate—osteoporosis	0.000931	0.00114	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Estradiol—osteoporosis	0.000931	0.00114	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Estradiol—osteoporosis	0.000928	0.00114	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Estradiol—osteoporosis	0.000926	0.00114	CcSEcCtD
Dabigatran etexilate—Rash—Etidronic acid—osteoporosis	0.000925	0.00113	CcSEcCtD
Dabigatran etexilate—Dermatitis—Etidronic acid—osteoporosis	0.000924	0.00113	CcSEcCtD
Dabigatran etexilate—Syncope—Conjugated Estrogens—osteoporosis	0.000921	0.00113	CcSEcCtD
Dabigatran etexilate—Hypertension—Zoledronate—osteoporosis	0.000921	0.00113	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Alendronate—osteoporosis	0.000921	0.00113	CcSEcCtD
Dabigatran etexilate—Headache—Etidronic acid—osteoporosis	0.000919	0.00113	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000914	0.00112	CcSEcCtD
Dabigatran etexilate—Asthenia—Estropipate—osteoporosis	0.00091	0.00112	CcSEcCtD
Dabigatran etexilate—Arthralgia—Zoledronate—osteoporosis	0.000908	0.00111	CcSEcCtD
Dabigatran etexilate—Chest pain—Zoledronate—osteoporosis	0.000908	0.00111	CcSEcCtD
Dabigatran etexilate—Palpitations—Conjugated Estrogens—osteoporosis	0.000908	0.00111	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000903	0.00111	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000902	0.00111	CcSEcCtD
Dabigatran etexilate—Pruritus—Estropipate—osteoporosis	0.000898	0.0011	CcSEcCtD
Dabigatran etexilate—Asthenia—Alendronate—osteoporosis	0.000897	0.0011	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Ibandronate—osteoporosis	0.000897	0.0011	CcSEcCtD
Dabigatran etexilate—Cough—Conjugated Estrogens—osteoporosis	0.000897	0.0011	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Risedronate—osteoporosis	0.000894	0.0011	CcSEcCtD
Dabigatran etexilate—Hypotension—Pamidronate—osteoporosis	0.000891	0.00109	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000888	0.00109	CcSEcCtD
Dabigatran etexilate—Fatigue—Ethinyl Estradiol—osteoporosis	0.000887	0.00109	CcSEcCtD
Dabigatran etexilate—Pruritus—Alendronate—osteoporosis	0.000884	0.00108	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Risedronate—osteoporosis	0.000883	0.00108	CcSEcCtD
Dabigatran etexilate—Constipation—Ethinyl Estradiol—osteoporosis	0.00088	0.00108	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Calcitriol—osteoporosis	0.000878	0.00108	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Estradiol—osteoporosis	0.000877	0.00108	CcSEcCtD
Dabigatran etexilate—Chest pain—Conjugated Estrogens—osteoporosis	0.000875	0.00107	CcSEcCtD
Dabigatran etexilate—Arthralgia—Conjugated Estrogens—osteoporosis	0.000875	0.00107	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—MTHFR—osteoporosis	0.000874	0.00473	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Ibandronate—osteoporosis	0.000873	0.00107	CcSEcCtD
Dabigatran etexilate—Nausea—Etidronic acid—osteoporosis	0.000871	0.00107	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Zoledronate—osteoporosis	0.000871	0.00107	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000869	0.00107	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000869	0.00107	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Estropipate—osteoporosis	0.000868	0.00106	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Risedronate—osteoporosis	0.000866	0.00106	CcSEcCtD
Dabigatran etexilate—Infection—Zoledronate—osteoporosis	0.000865	0.00106	CcSEcCtD
Dabigatran etexilate—Fatigue—Risedronate—osteoporosis	0.000865	0.00106	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—RAP1A—osteoporosis	0.000862	0.00467	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Ibandronate—osteoporosis	0.000861	0.00106	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—CAP1—osteoporosis	0.00086	0.00466	CbGpPWpGaD
Dabigatran etexilate—Constipation—Risedronate—osteoporosis	0.000858	0.00105	CcSEcCtD
Dabigatran etexilate—Angiopathy—Estradiol—osteoporosis	0.000857	0.00105	CcSEcCtD
Dabigatran etexilate—Shock—Zoledronate—osteoporosis	0.000857	0.00105	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Alendronate—osteoporosis	0.000855	0.00105	CcSEcCtD
Dabigatran etexilate—Asthenia—Calcitriol—osteoporosis	0.000855	0.00105	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Zoledronate—osteoporosis	0.000854	0.00105	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Estradiol—osteoporosis	0.000853	0.00105	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Zoledronate—osteoporosis	0.000853	0.00105	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Estradiol—osteoporosis	0.000851	0.00104	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Pamidronate—osteoporosis	0.00085	0.00104	CcSEcCtD
Dabigatran etexilate—Skin disorder—Zoledronate—osteoporosis	0.000846	0.00104	CcSEcCtD
Dabigatran etexilate—Pruritus—Calcitriol—osteoporosis	0.000843	0.00103	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000841	0.00103	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Raloxifene—osteoporosis	0.000841	0.00103	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Pamidronate—osteoporosis	0.000839	0.00103	CcSEcCtD
Dabigatran etexilate—Dizziness—Estropipate—osteoporosis	0.000839	0.00103	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000839	0.00103	CcSEcCtD
Dabigatran etexilate—UGT2B15—Biological oxidations—POMC—osteoporosis	0.000837	0.00453	CbGpPWpGaD
Dabigatran etexilate—Infection—Conjugated Estrogens—osteoporosis	0.000833	0.00102	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Ibandronate—osteoporosis	0.000833	0.00102	CcSEcCtD
Dabigatran etexilate—Dizziness—Alendronate—osteoporosis	0.000827	0.00101	CcSEcCtD
Dabigatran etexilate—Shock—Conjugated Estrogens—osteoporosis	0.000825	0.00101	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000823	0.00101	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000822	0.00101	CcSEcCtD
Dabigatran etexilate—Malnutrition—Estradiol—osteoporosis	0.000822	0.00101	CcSEcCtD
Dabigatran etexilate—Fatigue—Pamidronate—osteoporosis	0.000822	0.00101	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Risedronate—osteoporosis	0.00082	0.00101	CcSEcCtD
Dabigatran etexilate—Urticaria—Ethinyl Estradiol—osteoporosis	0.000817	0.001	CcSEcCtD
Dabigatran etexilate—Constipation—Pamidronate—osteoporosis	0.000815	0.001	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Calcitriol—osteoporosis	0.000815	0.001	CcSEcCtD
Dabigatran etexilate—Skin disorder—Conjugated Estrogens—osteoporosis	0.000814	0.000999	CcSEcCtD
Dabigatran etexilate—Hypotension—Zoledronate—osteoporosis	0.000814	0.000998	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000813	0.000997	CcSEcCtD
Dabigatran etexilate—Dizziness—Raloxifene—osteoporosis	0.000813	0.000997	CcSEcCtD
Dabigatran etexilate—UGT1A9—PPAR Alpha Pathway—MYC—osteoporosis	0.000812	0.0044	CbGpPWpGaD
Dabigatran etexilate—Flatulence—Estradiol—osteoporosis	0.00081	0.000994	CcSEcCtD
Dabigatran etexilate—Vomiting—Estropipate—osteoporosis	0.000807	0.00099	CcSEcCtD
Dabigatran etexilate—Dizziness—Ibandronate—osteoporosis	0.000805	0.000987	CcSEcCtD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—IL1B—osteoporosis	0.000803	0.00435	CbGpPWpGaD
Dabigatran etexilate—Rash—Estropipate—osteoporosis	0.0008	0.000981	CcSEcCtD
Dabigatran etexilate—Dermatitis—Estropipate—osteoporosis	0.000799	0.00098	CcSEcCtD
Dabigatran etexilate—Urticaria—Risedronate—osteoporosis	0.000797	0.000977	CcSEcCtD
Dabigatran etexilate—Back pain—Estradiol—osteoporosis	0.000795	0.000976	CcSEcCtD
Dabigatran etexilate—Headache—Estropipate—osteoporosis	0.000795	0.000975	CcSEcCtD
Dabigatran etexilate—Vomiting—Alendronate—osteoporosis	0.000795	0.000975	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000793	0.000973	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Risedronate—osteoporosis	0.000793	0.000972	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—FDPS—osteoporosis	0.00079	0.00428	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PKM—osteoporosis	0.00079	0.00428	CbGpPWpGaD
Dabigatran etexilate—Rash—Alendronate—osteoporosis	0.000788	0.000967	CcSEcCtD
Dabigatran etexilate—Dermatitis—Alendronate—osteoporosis	0.000787	0.000966	CcSEcCtD
Dabigatran etexilate—Hypotension—Conjugated Estrogens—osteoporosis	0.000784	0.000961	CcSEcCtD
Dabigatran etexilate—Headache—Alendronate—osteoporosis	0.000783	0.00096	CcSEcCtD
Dabigatran etexilate—Vomiting—Raloxifene—osteoporosis	0.000782	0.000959	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—FGA—osteoporosis	0.000781	0.00423	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Pamidronate—osteoporosis	0.00078	0.000956	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Zoledronate—osteoporosis	0.000776	0.000952	CcSEcCtD
Dabigatran etexilate—Rash—Raloxifene—osteoporosis	0.000775	0.000951	CcSEcCtD
Dabigatran etexilate—Dermatitis—Raloxifene—osteoporosis	0.000774	0.00095	CcSEcCtD
Dabigatran etexilate—Vomiting—Ibandronate—osteoporosis	0.000774	0.000949	CcSEcCtD
Dabigatran etexilate—Headache—Raloxifene—osteoporosis	0.00077	0.000944	CcSEcCtD
Dabigatran etexilate—Rash—Ibandronate—osteoporosis	0.000767	0.000941	CcSEcCtD
Dabigatran etexilate—Dermatitis—Ibandronate—osteoporosis	0.000767	0.00094	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Zoledronate—osteoporosis	0.000767	0.00094	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000764	0.000937	CcSEcCtD
Dabigatran etexilate—Headache—Ibandronate—osteoporosis	0.000762	0.000935	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—MYC—osteoporosis	0.000762	0.00413	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000758	0.000929	CcSEcCtD
Dabigatran etexilate—Vomiting—Calcitriol—osteoporosis	0.000757	0.000929	CcSEcCtD
Dabigatran etexilate—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000756	0.0041	CbGpPWpGaD
Dabigatran etexilate—Nausea—Estropipate—osteoporosis	0.000754	0.000924	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Pamidronate—osteoporosis	0.000754	0.000924	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000752	0.000922	CcSEcCtD
Dabigatran etexilate—Angioedema—Estradiol—osteoporosis	0.000751	0.000922	CcSEcCtD
Dabigatran etexilate—Rash—Calcitriol—osteoporosis	0.000751	0.000921	CcSEcCtD
Dabigatran etexilate—Fatigue—Zoledronate—osteoporosis	0.000751	0.000921	CcSEcCtD
Dabigatran etexilate—Dermatitis—Calcitriol—osteoporosis	0.00075	0.00092	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—PGLS—osteoporosis	0.000749	0.00405	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GPD2—osteoporosis	0.000749	0.00405	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000748	0.000917	CcSEcCtD
Dabigatran etexilate—Headache—Calcitriol—osteoporosis	0.000746	0.000915	CcSEcCtD
Dabigatran etexilate—Constipation—Zoledronate—osteoporosis	0.000745	0.000913	CcSEcCtD
Dabigatran etexilate—Nausea—Alendronate—osteoporosis	0.000742	0.000911	CcSEcCtD
Dabigatran etexilate—CES2—NRF2 pathway—TGFB1—osteoporosis	0.000741	0.00401	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Risedronate—osteoporosis	0.000739	0.000906	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000738	0.000905	CcSEcCtD
Dabigatran etexilate—Asthenia—Ethinyl Estradiol—osteoporosis	0.000738	0.000905	CcSEcCtD
Dabigatran etexilate—Syncope—Estradiol—osteoporosis	0.000737	0.000904	CcSEcCtD
Dabigatran etexilate—Nausea—Raloxifene—osteoporosis	0.00073	0.000896	CcSEcCtD
Dabigatran etexilate—Pruritus—Ethinyl Estradiol—osteoporosis	0.000728	0.000893	CcSEcCtD
Dabigatran etexilate—Palpitations—Estradiol—osteoporosis	0.000727	0.000891	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000724	0.000888	CcSEcCtD
Dabigatran etexilate—Fatigue—Conjugated Estrogens—osteoporosis	0.000723	0.000887	CcSEcCtD
Dabigatran etexilate—Nausea—Ibandronate—osteoporosis	0.000723	0.000887	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Estradiol—osteoporosis	0.000723	0.000886	CcSEcCtD
Dabigatran etexilate—Asthenia—Risedronate—osteoporosis	0.00072	0.000883	CcSEcCtD
Dabigatran etexilate—Cough—Estradiol—osteoporosis	0.000718	0.00088	CcSEcCtD
Dabigatran etexilate—Constipation—Conjugated Estrogens—osteoporosis	0.000717	0.000879	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Zoledronate—osteoporosis	0.000712	0.000873	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—FGB—osteoporosis	0.000711	0.00385	CbGpPWpGaD
Dabigatran etexilate—Hypertension—Estradiol—osteoporosis	0.00071	0.000871	CcSEcCtD
Dabigatran etexilate—Pruritus—Risedronate—osteoporosis	0.00071	0.00087	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—CCT2—osteoporosis	0.000709	0.00384	CbGpPWpGaD
Dabigatran etexilate—Nausea—Calcitriol—osteoporosis	0.000708	0.000868	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000704	0.000863	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Pamidronate—osteoporosis	0.000702	0.000861	CcSEcCtD
Dabigatran etexilate—Arthralgia—Estradiol—osteoporosis	0.0007	0.000859	CcSEcCtD
Dabigatran etexilate—Chest pain—Estradiol—osteoporosis	0.0007	0.000859	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000695	0.000853	CcSEcCtD
Dabigatran etexilate—Urticaria—Zoledronate—osteoporosis	0.000692	0.000848	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Zoledronate—osteoporosis	0.000688	0.000844	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Risedronate—osteoporosis	0.000686	0.000842	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000686	0.000841	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—ATIC—osteoporosis	0.000685	0.00371	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PNP—osteoporosis	0.000685	0.00371	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Pamidronate—osteoporosis	0.000684	0.000839	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—MGLL—osteoporosis	0.000683	0.0037	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Ethinyl Estradiol—osteoporosis	0.00068	0.000834	CcSEcCtD
Dabigatran etexilate—Pruritus—Pamidronate—osteoporosis	0.000674	0.000827	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Estradiol—osteoporosis	0.000671	0.000823	CcSEcCtD
Dabigatran etexilate—Infection—Estradiol—osteoporosis	0.000667	0.000818	CcSEcCtD
Dabigatran etexilate—Urticaria—Conjugated Estrogens—osteoporosis	0.000666	0.000817	CcSEcCtD
Dabigatran etexilate—Dizziness—Risedronate—osteoporosis	0.000663	0.000813	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000663	0.000813	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL1B—osteoporosis	0.000661	0.00358	CbGpPWpGaD
Dabigatran etexilate—Shock—Estradiol—osteoporosis	0.00066	0.00081	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Estradiol—osteoporosis	0.000658	0.000807	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000656	0.00355	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Ethinyl Estradiol—osteoporosis	0.000654	0.000802	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—IL1B—osteoporosis	0.000653	0.00354	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Pamidronate—osteoporosis	0.000652	0.0008	CcSEcCtD
Dabigatran etexilate—Skin disorder—Estradiol—osteoporosis	0.000652	0.000799	CcSEcCtD
Dabigatran etexilate—Rash—Ethinyl Estradiol—osteoporosis	0.000649	0.000795	CcSEcCtD
Dabigatran etexilate—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000648	0.000795	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.000647	0.0035	CbGpPWpGaD
Dabigatran etexilate—Headache—Ethinyl Estradiol—osteoporosis	0.000644	0.00079	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Zoledronate—osteoporosis	0.000642	0.000787	CcSEcCtD
Dabigatran etexilate—Vomiting—Risedronate—osteoporosis	0.000638	0.000782	CcSEcCtD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—ENO1—osteoporosis	0.000637	0.00345	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Biological oxidations—CYP19A1—osteoporosis	0.000635	0.00344	CbGpPWpGaD
Dabigatran etexilate—Rash—Risedronate—osteoporosis	0.000632	0.000776	CcSEcCtD
Dabigatran etexilate—Dermatitis—Risedronate—osteoporosis	0.000632	0.000775	CcSEcCtD
Dabigatran etexilate—Dizziness—Pamidronate—osteoporosis	0.00063	0.000773	CcSEcCtD
Dabigatran etexilate—Headache—Risedronate—osteoporosis	0.000628	0.000771	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—CYP19A1—osteoporosis	0.000626	0.00339	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PLEK—osteoporosis	0.000625	0.00339	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—ANXA2—osteoporosis	0.000625	0.00339	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Zoledronate—osteoporosis	0.000625	0.000766	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000622	0.00337	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000618	0.000758	CcSEcCtD
Dabigatran etexilate—Pruritus—Zoledronate—osteoporosis	0.000616	0.000756	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000611	0.00075	CcSEcCtD
Dabigatran etexilate—Nausea—Ethinyl Estradiol—osteoporosis	0.000611	0.000749	CcSEcCtD
Dabigatran etexilate—Vomiting—Pamidronate—osteoporosis	0.000606	0.000743	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—TUBA1B—osteoporosis	0.000603	0.00327	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Conjugated Estrogens—osteoporosis	0.000602	0.000738	CcSEcCtD
Dabigatran etexilate—Rash—Pamidronate—osteoporosis	0.000601	0.000737	CcSEcCtD
Dabigatran etexilate—Dermatitis—Pamidronate—osteoporosis	0.000601	0.000737	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Estradiol—osteoporosis	0.000598	0.000734	CcSEcCtD
Dabigatran etexilate—Headache—Pamidronate—osteoporosis	0.000597	0.000733	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Zoledronate—osteoporosis	0.000596	0.000731	CcSEcCtD
Dabigatran etexilate—Nausea—Risedronate—osteoporosis	0.000596	0.000731	CcSEcCtD
Dabigatran etexilate—UGT2B7—NRF2 pathway—AGER—osteoporosis	0.000593	0.00321	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Conjugated Estrogens—osteoporosis	0.000593	0.000728	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—TNF—osteoporosis	0.000592	0.0032	CbGpPWpGaD
Dabigatran etexilate—Dyspepsia—Estradiol—osteoporosis	0.000591	0.000725	CcSEcCtD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—TNF—osteoporosis	0.000582	0.00315	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CA2—osteoporosis	0.000582	0.00315	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—OXCT1—osteoporosis	0.000582	0.00315	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal disorder—Estradiol—osteoporosis	0.000579	0.000711	CcSEcCtD
Dabigatran etexilate—Fatigue—Estradiol—osteoporosis	0.000579	0.00071	CcSEcCtD
Dabigatran etexilate—Dizziness—Zoledronate—osteoporosis	0.000576	0.000706	CcSEcCtD
Dabigatran etexilate—Constipation—Estradiol—osteoporosis	0.000574	0.000704	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000574	0.000704	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—MGLL—osteoporosis	0.000567	0.00307	CbGpPWpGaD
Dabigatran etexilate—Nausea—Pamidronate—osteoporosis	0.000566	0.000695	CcSEcCtD
Dabigatran etexilate—Dizziness—Conjugated Estrogens—osteoporosis	0.000554	0.00068	CcSEcCtD
Dabigatran etexilate—Vomiting—Zoledronate—osteoporosis	0.000554	0.000679	CcSEcCtD
Dabigatran etexilate—Rash—Zoledronate—osteoporosis	0.000549	0.000673	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Estradiol—osteoporosis	0.000549	0.000673	CcSEcCtD
Dabigatran etexilate—Dermatitis—Zoledronate—osteoporosis	0.000549	0.000673	CcSEcCtD
Dabigatran etexilate—Headache—Zoledronate—osteoporosis	0.000546	0.000669	CcSEcCtD
Dabigatran etexilate—F2—GPCR downstream signaling—PTH1R—osteoporosis	0.000544	0.00294	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CALCR—osteoporosis	0.000544	0.00294	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TLN1—osteoporosis	0.000539	0.00292	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Conjugated Estrogens—osteoporosis	0.000533	0.000654	CcSEcCtD
Dabigatran etexilate—Urticaria—Estradiol—osteoporosis	0.000533	0.000654	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—VCL—osteoporosis	0.000532	0.00288	CbGpPWpGaD
Dabigatran etexilate—Abdominal pain—Estradiol—osteoporosis	0.000531	0.000651	CcSEcCtD
Dabigatran etexilate—Rash—Conjugated Estrogens—osteoporosis	0.000529	0.000648	CcSEcCtD
Dabigatran etexilate—Dermatitis—Conjugated Estrogens—osteoporosis	0.000528	0.000648	CcSEcCtD
Dabigatran etexilate—Headache—Conjugated Estrogens—osteoporosis	0.000525	0.000644	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—IL1B—osteoporosis	0.000519	0.00281	CbGpPWpGaD
Dabigatran etexilate—Nausea—Zoledronate—osteoporosis	0.000517	0.000634	CcSEcCtD
Dabigatran etexilate—UGT1A9—Biological oxidations—CYP19A1—osteoporosis	0.000516	0.00279	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—osteoporosis	0.000513	0.00278	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—CYP19A1—osteoporosis	0.000509	0.00275	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—PTH—osteoporosis	0.000505	0.00274	CbGpPWpGaD
Dabigatran etexilate—Nausea—Conjugated Estrogens—osteoporosis	0.000498	0.000611	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Estradiol—osteoporosis	0.000494	0.000606	CcSEcCtD
Dabigatran etexilate—F2—Signaling by GPCR—CALCR—osteoporosis	0.000494	0.00267	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PTH1R—osteoporosis	0.000494	0.00267	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CNR2—osteoporosis	0.000493	0.00267	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000484	0.00262	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—IDH2—osteoporosis	0.000482	0.00261	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—RPL24—osteoporosis	0.000482	0.00261	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—AGER—osteoporosis	0.000482	0.00261	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Estradiol—osteoporosis	0.000481	0.000591	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—osteoporosis	0.000479	0.0026	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Estradiol—osteoporosis	0.000475	0.000582	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—TNF—osteoporosis	0.000474	0.00257	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000472	0.00255	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—IL6—osteoporosis	0.00047	0.00255	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—WNT1—osteoporosis	0.000463	0.00251	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Estradiol—osteoporosis	0.000459	0.000563	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—CYP27A1—osteoporosis	0.000454	0.00246	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—RAP1A—osteoporosis	0.000444	0.00241	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Estradiol—osteoporosis	0.000444	0.000544	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—ACP5—osteoporosis	0.000441	0.00239	CbGpPWpGaD
Dabigatran etexilate—CES1—NRF2 pathway—TGFB1—osteoporosis	0.000437	0.00236	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—MGLL—osteoporosis	0.000432	0.00234	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Estradiol—osteoporosis	0.000427	0.000523	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—TLN1—osteoporosis	0.000424	0.0023	CbGpPWpGaD
Dabigatran etexilate—Rash—Estradiol—osteoporosis	0.000423	0.000519	CcSEcCtD
Dabigatran etexilate—Dermatitis—Estradiol—osteoporosis	0.000423	0.000518	CcSEcCtD
Dabigatran etexilate—Headache—Estradiol—osteoporosis	0.00042	0.000516	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—PTHLH—osteoporosis	0.000419	0.00227	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—TPI1—osteoporosis	0.00041	0.00222	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—REN—osteoporosis	0.000407	0.00221	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—FGA—osteoporosis	0.000403	0.00218	CbGpPWpGaD
Dabigatran etexilate—Nausea—Estradiol—osteoporosis	0.000399	0.000489	CcSEcCtD
Dabigatran etexilate—F2—Signaling by GPCR—MGLL—osteoporosis	0.000392	0.00212	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—P4HB—osteoporosis	0.000386	0.00209	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—IL6—osteoporosis	0.000382	0.00207	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Biological oxidations—POMC—osteoporosis	0.000381	0.00207	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GAPDH—osteoporosis	0.000379	0.00205	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—POMC—osteoporosis	0.000378	0.00205	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000377	0.00204	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—TNF—osteoporosis	0.000376	0.00204	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—RAP1A—osteoporosis	0.000369	0.002	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CALCA—osteoporosis	0.000369	0.002	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—FGB—osteoporosis	0.000366	0.00198	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—FDPS—osteoporosis	0.00036	0.00195	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PKM—osteoporosis	0.00036	0.00195	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—LEP—osteoporosis	0.000356	0.00193	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PGLS—osteoporosis	0.000341	0.00185	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GPD2—osteoporosis	0.000341	0.00185	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.000337	0.00182	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000334	0.00181	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SOST—osteoporosis	0.000323	0.00175	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—IGF1—osteoporosis	0.000322	0.00174	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000321	0.00174	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ATIC—osteoporosis	0.000312	0.00169	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PNP—osteoporosis	0.000312	0.00169	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Biological oxidations—POMC—osteoporosis	0.00031	0.00168	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—IL6—osteoporosis	0.000304	0.00165	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ENO1—osteoporosis	0.000298	0.00161	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PSMA2—osteoporosis	0.000294	0.00159	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PSMA5—osteoporosis	0.000294	0.00159	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PKM—osteoporosis	0.000292	0.00158	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—FDPS—osteoporosis	0.000292	0.00158	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CALCR—osteoporosis	0.000292	0.00158	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTH1R—osteoporosis	0.000292	0.00158	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PTH—osteoporosis	0.000286	0.00155	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CNR2—osteoporosis	0.000278	0.00151	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PGLS—osteoporosis	0.000277	0.0015	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GPD2—osteoporosis	0.000277	0.0015	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CA2—osteoporosis	0.000265	0.00144	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—OXCT1—osteoporosis	0.000265	0.00144	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PTH—osteoporosis	0.000259	0.0014	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—MGLL—osteoporosis	0.000258	0.0014	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—ACE—osteoporosis	0.000254	0.00138	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PNP—osteoporosis	0.000253	0.00137	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ATIC—osteoporosis	0.000253	0.00137	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000253	0.00137	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CNR2—osteoporosis	0.000253	0.00137	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—TGFB1—osteoporosis	0.000251	0.00136	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	0.00024	0.0013	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CYP19A1—osteoporosis	0.000238	0.00129	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—WNT1—osteoporosis	0.000238	0.00129	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PTHLH—osteoporosis	0.000237	0.00128	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MGLL—osteoporosis	0.000232	0.00125	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—LRP5—osteoporosis	0.000226	0.00122	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	0.000224	0.00122	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—IDH2—osteoporosis	0.00022	0.00119	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—LRP6—osteoporosis	0.000216	0.00117	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—OXCT1—osteoporosis	0.000216	0.00117	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CA2—osteoporosis	0.000216	0.00117	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PTHLH—osteoporosis	0.000215	0.00116	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—MGLL—osteoporosis	0.00021	0.00114	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CALCA—osteoporosis	0.000208	0.00113	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP27A1—osteoporosis	0.000207	0.00112	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—TGFB1—osteoporosis	0.000204	0.0011	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ACP5—osteoporosis	0.000201	0.00109	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	0.000198	0.00107	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL1B—osteoporosis	0.000197	0.00106	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ADCY5—osteoporosis	0.000195	0.00105	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GPX1—osteoporosis	0.000194	0.00105	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	0.000193	0.00105	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—POMC—osteoporosis	0.000193	0.00104	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CALCA—osteoporosis	0.000189	0.00102	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000188	0.00102	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TPI1—osteoporosis	0.000187	0.00101	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TLN1—osteoporosis	0.000183	0.000989	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—MTHFR—osteoporosis	0.000179	0.00097	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—IDH2—osteoporosis	0.000179	0.000967	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—P4HB—osteoporosis	0.000176	0.000951	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GAPDH—osteoporosis	0.000172	0.000934	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—RAP1A—osteoporosis	0.000168	0.00091	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP27A1—osteoporosis	0.000168	0.000909	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IGF1—osteoporosis	0.000166	0.000899	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ACP5—osteoporosis	0.000163	0.000884	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	0.000161	0.000873	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—LEP—osteoporosis	0.000158	0.000855	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—P4HB—osteoporosis	0.000158	0.000853	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTH—osteoporosis	0.000153	0.00083	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TGFB1—osteoporosis	0.000153	0.000827	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TPI1—osteoporosis	0.000152	0.000822	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RAP1A—osteoporosis	0.000151	0.000815	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CNR2—osteoporosis	0.000149	0.000809	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	0.000149	0.000805	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—ADCY5—osteoporosis	0.000148	0.000803	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NFATC1—osteoporosis	0.000147	0.000796	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—DKK1—osteoporosis	0.000146	0.000789	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	0.000145	0.000787	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—POMC—osteoporosis	0.000143	0.000776	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—P4HB—osteoporosis	0.000143	0.000773	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TNF—osteoporosis	0.000143	0.000773	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—WNT1—osteoporosis	0.00014	0.00076	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GAPDH—osteoporosis	0.00014	0.000759	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGA—osteoporosis	0.000137	0.00074	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—RAP1A—osteoporosis	0.000136	0.000739	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ENO1—osteoporosis	0.000136	0.000735	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—POMC—osteoporosis	0.000136	0.000735	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—ADCY5—osteoporosis	0.000135	0.000729	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PKM—osteoporosis	0.000134	0.000726	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—FDPS—osteoporosis	0.000134	0.000726	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PSMA5—osteoporosis	0.000134	0.000724	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PSMA2—osteoporosis	0.000134	0.000724	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—IGF1—osteoporosis	0.000131	0.000707	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GPD2—osteoporosis	0.000127	0.000688	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PGLS—osteoporosis	0.000127	0.000688	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—BMP2—osteoporosis	0.000127	0.000688	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTHLH—osteoporosis	0.000127	0.000688	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	0.000126	0.000681	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGB—osteoporosis	0.000124	0.000673	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PSMA5—osteoporosis	0.00012	0.00065	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PSMA2—osteoporosis	0.00012	0.00065	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	0.000119	0.000645	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PNP—osteoporosis	0.000116	0.00063	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ATIC—osteoporosis	0.000116	0.00063	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CALCA—osteoporosis	0.000112	0.000605	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ENO1—osteoporosis	0.00011	0.000597	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—POMC—osteoporosis	0.000109	0.00059	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PSMA2—osteoporosis	0.000109	0.000589	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PSMA5—osteoporosis	0.000109	0.000589	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP19A1—osteoporosis	0.000109	0.000588	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KL—osteoporosis	0.000101	0.00055	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TGFB1—osteoporosis	9.95e-05	0.000539	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—POMC—osteoporosis	9.9e-05	0.000536	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CA2—osteoporosis	9.89e-05	0.000535	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—OXCT1—osteoporosis	9.89e-05	0.000535	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL6R—osteoporosis	9.66e-05	0.000523	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MGLL—osteoporosis	9.63e-05	0.000522	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ADCY5—osteoporosis	8.87e-05	0.00048	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GPX1—osteoporosis	8.84e-05	0.000479	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP19A1—osteoporosis	8.82e-05	0.000478	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—IDH2—osteoporosis	8.19e-05	0.000444	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—MTHFR—osteoporosis	8.16e-05	0.000442	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ADCY5—osteoporosis	7.95e-05	0.000431	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP27A1—osteoporosis	7.7e-05	0.000417	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SPP1—osteoporosis	7.69e-05	0.000417	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	7.56e-05	0.000409	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	7.54e-05	0.000408	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ACP5—osteoporosis	7.49e-05	0.000406	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ADCY5—osteoporosis	7.21e-05	0.00039	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GPX1—osteoporosis	7.18e-05	0.000389	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	7.06e-05	0.000382	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	7.04e-05	0.000381	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TPI1—osteoporosis	6.97e-05	0.000377	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IRS2—osteoporosis	6.96e-05	0.000377	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—LEP—osteoporosis	6.81e-05	0.000369	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—MTHFR—osteoporosis	6.63e-05	0.000359	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—P4HB—osteoporosis	6.55e-05	0.000355	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—POMC—osteoporosis	6.52e-05	0.000353	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ESR1—osteoporosis	6.5e-05	0.000352	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GAPDH—osteoporosis	6.43e-05	0.000348	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—RAP1A—osteoporosis	6.26e-05	0.000339	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IRS1—osteoporosis	6.07e-05	0.000329	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—POMC—osteoporosis	5.85e-05	0.000317	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL6R—osteoporosis	5.7e-05	0.000309	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IGF1—osteoporosis	5.63e-05	0.000305	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—POMC—osteoporosis	5.3e-05	0.000287	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ENO1—osteoporosis	5.06e-05	0.000274	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PSMA5—osteoporosis	4.99e-05	0.00027	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PSMA2—osteoporosis	4.99e-05	0.00027	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL6—osteoporosis	4.3e-05	0.000233	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP19A1—osteoporosis	4.05e-05	0.000219	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—osteoporosis	3.38e-05	0.000183	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TGFB1—osteoporosis	3.37e-05	0.000183	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ADCY5—osteoporosis	3.31e-05	0.000179	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GPX1—osteoporosis	3.29e-05	0.000178	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MTHFR—osteoporosis	3.04e-05	0.000165	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL6—osteoporosis	2.54e-05	0.000138	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—POMC—osteoporosis	2.43e-05	0.000132	CbGpPWpGaD
